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Edited by Amy McGoughAbstract b-Amyloid peptide (Ab) is the major constituent of
senile plaques, the key pathological feature of Alzheimers dis-
ease. Ab is physiologically produced as a soluble form, but
aggregation of Ab monomers into oligomers/ﬁbrils causes neuro-
toxic change of the peptide. In nature, many microorganisms
accumulate small molecule chaperones (SMCs) under stressful
conditions to prevent the misfolding/denaturation of proteins
and to maintain their stability. Hence, it is conceivable that
SMCs such as ectoine and hydroxyectoine could be potential
inhibitors against the aggregate formation of Alzheimers Ab,
which has not been studied to date. The current work shows
the eﬀectiveness of ectoine and hydroxyectoine on the inhibition
of Ab42 aggregation and toxicity to human neuroblastoma cells.
The characterization tools used for this study include thioﬂavin-
T induced ﬂuorescence, atomic force microscopy and cell viabil-
ity assay. Considering that ectoine and hydroxyectoine are not
toxic to cellular environment even at concentrations as high as
100 mM, the results may suggest a basis for the development
of ectoines as potential inhibitors associated with neurodegener-
ative diseases.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Alzheimers disease (AD), currently aﬀecting about 10% of
the population age 65 and over, is characterized by the pres-
ence of extracellular amyloid plaques and neuroﬁbrilliary tan-
gles in the brain tissue [1,2]. The major component of the
amyloid plaques is a 39–42 residues peptide termed b-amyloid
peptide (Ab), which is produced in soluble forms by proteoly-
sis of b-amyloid precursor protein [3]. Although several seg-
ments of Ab fragments are generated during this proteolysis
process, the 42-amino acids version (Ab42) has been shown
to have a high propensity to aggregate and was found to be
the most predominant in amyloid plaques [3,4]. Environmental
stresses are known to trigger the formation of amyloid aggre-
gates having cross b-sheet secondary structure [5–9]. While
there are no eﬀective treatments for AD at the present time,
substances that can eﬃciently inhibit the amyloid formation*Corresponding author. Fax: +1 480 965 0037.
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doi:10.1016/j.febslet.2005.07.057by interfering with the process have been sought as drug can-
didates for treating AD [10–15].
Ectoines are common solutes of aerobic heterotrophic bacte-
ria and constitute a class of small molecule chaperones
(SMCs). SMCs accumulate to high intracellular concentra-
tions, preventing the misfolding/denaturation of proteins and
other labile macromolecular structures from environmental
stresses [16–19]. The presence of SMCs has already proven
highly eﬀective in preserving enzymatic activities against heat-
ing, freezing and drying [19,20]. Recently, we reported that
SMCs like ectoine, betaine, trehalose, citrulline could success-
fully inhibit insulin amyloid formation in vitro [21]. Those
ﬁndings suggest the eﬃcacy of SMCs against amyloid forma-
tion, which may make them viable drug candidates for treating
neurodegenerative diseases in the future.
Ectoine (1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carbox-
ylic acid) is one of the most abundant osmolytes in nature [22].
It has been reported that ectoine protects proteins and enzymes
from thermal stress, proteolysis, change of the pH or the salt
concentration; their ability to stabilize diﬀerent proteins, nucleic
acids, membranes and whole cells is well studied [19,20,23–26].
Hydroxyectoine is a derivative of ectoine diﬀering in chemical
structure by a hydroxyl group (Fig. 1). It is produced by halo-
philic bacteria under elevated temperature conditions and acts
as general dessication protectant for bacterial cells [27]. In the
present work, we report that ectoine and hydroxyectoine
strongly inhibit the Ab42 amyloid formation in vitro and reduce
the toxicity to human neuroblastoma cells. This ﬁnding suggests
that ectoine andhydroxyectoine couldbepotential candidates of
anti-amyloid therapeutics for treating AD.2. Materials and methods
2.1. In vitro Ab42 amyloid formation
Human Ab42 was purchased from rPeptide Co. (Athens, GA, USA).
Ectoines were obtained from Sigma–Aldrich Co. (St. Louis, MO,
USA) and Bitop AG (Witten, Germany). All other chemicals and
reagents were purchased from Sigma–Aldrich Co. Ab42 was dissolved
in 100% hexaﬂuoroisopropanol and was sonicated in water bath for
5 min. The dissolved peptide was aliquoted in microcentrifuge tubes,
left at room temperature for half an hour, then dried with nitrogen
gas and stored at 20 C. Ab42 aggregates were formed in 10 mM
HCl with 2% DMSO at a concentration of 25 lM at 37 C for three
days according to [28]. Incubation took place in sealed glass vials to
prevent any possible evaporation. Ectoines were prepared as stock
solutions of 1 M in deionized water before use. For observing the eﬀect
on SH-SY5Y cell viability, Ab42 seed samples were prepared by incu-
bating 25 or 100 lM solution (10 mM HCl, 2% DMSO) at 37 C for
24 h.blished by Elsevier B.V. All rights reserved.
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Fig. 1. Chemical structures of ectoine and hydroxyectoine.
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Fig. 2. Eﬀect of: (A) ectoine and (B) hydroxyectoine on Ab42 amyloid
formation. ThT-induced ﬂuorescence changes were measured for Ab42
(25 lM) solution incubated without/with ectoine or hydroxyectoine a
37 C for 72 h.
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Thioﬂavin T (ThT)-induced ﬂuorescence changes were measured by
spectroﬂuorophotometer (Model RF5301, Shimadzu Co., Japan)
according to [29]. The sample (5 ll) was mixed with 1.5 ml of 50 lM
ThT solution in Tris–HCl buﬀer (pH 8, 20 mM) in a quartz cuvette.
Ectoine or hydroxyectoine itself did not interfere with ThT-induced
ﬂuorescence. The ﬂuorescence intensity was monitored at an excitation
wavelength of 450 nm and an emission wavelength of 482 nm with
excitation and emission slit widths at 5 nm each. Readings were done
in triplicate and the average was taken as the ﬁnal value. These average
readings were then subtracted from the reading of the ThT-only solu-
tion. The results were then normalized against the control Ab42
sample.
2.3. MTT assay
Human neuroblastoma cells (SH-SY5Y) were maintained in med-
ium with 40% minimal essential medium (MEM), 40% Hams modiﬁ-
cation of F-12, 18% fetal bovine serum (FBS), 1% L-glutamine
(3.6 mM), and 1% penicillin/streptomycin antibiotics in 5% CO2 at
37 C. FBS, penicillin/streptomycin antibiotics and L-glutamine were
purchased from Invitrogen (Carlsbad, CA, USA). MEM and Hams
F-12 were purchased from Irvine Scientiﬁc (Santa Ana, CA, USA).
Cells were harvested from ﬂasks and plated at a concentration of
100 cells/ll medium per well in a 96-well polystyrene plate. Cells were
incubated at 37 C for 24 h to allow the cells to attach to the ﬂask.
Ab42 (25 or 100 lM) seed samples with/without ectoine or hydroxyec-
toine were preincubated for one day, followed by dilution to two dif-
ferent sets of concentrations (2.5 and 10 lM) with Tris–HCl buﬀer
buﬀer (pH 7.4, 20 mM). Each sample (10 ll) was then added to the
wells containing the cell culture (90 ll), resulting in ﬁnal concentra-
tions of the samples of either 0.25 or 1 lM. For testing the eﬀect of
ectoine or hydroxyectoine alone on the cell viability, ectoines were
prepared at concentrations of 250 lM, 10 mM, 100 mM and 1 M in
Tris–HCl buﬀer (pH 7.4, 20 mM) and were diluted 10 times by their
application to the cell culture. The treated cells were incubated for
an additional 48 h at 37 C. For the cell viability assay, 10 ll of
5 mg/ml MTT [(3,4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide] in deionized water were added to each well, and cell survival
was determined according to [30]. The medium was aspirated from the
centrifuged plates after 3 h incubation at 37 C and the solubilization
solution 100 ll of 2-propanol containing 0.1 N HCl was added to
the wells. The absorbance of each sample was measured at 560 nm
using a multi-well assay plate reader (Victor Wallac, Gaithersburg,
MD). Four replicate wells were used for each sample and control. Each
experiment was repeated twice, and the average value was calculated.
Cell viability was determined by dividing the sample absorbance values
by the control sample absorbance value.
2.4. Atomic force microscopy (AFM)
Samples were imaged with Nanoprobe III scanning probe worksta-
tion (Digital Instruments Inc., CA, USA) according to [31]. Samples
were prepared by placing 5 ll of solution on freshly cleaved mica
(Ted Pella Inc., Redding, CA) at room temperature for 60 s; they were
then washed twice with 50 ll of deionized water and dried with nitro-
gen gas. Image data was obtained in tapping mode under ambient con-
ditions at a scan frequency of 1–2 Hz with AFM tips (Veeco
Metrology, LLC, Santa Barbara, CA) operating at a resonant fre-
quency of 306–444 kHz. The spring constant of the cantilever having
the AFM tip was 103 N/m. The length and the width of the cantilever
were 140–180 and 48–52 lm, respectively. The range of oscillation
amplitudes and set points used here was 40–100 mV and 0.8–1.0 V,respectively. A scan area of 5 · 5 lm was imaged for two diﬀerent sam-
ples in each case. All images were ﬂattened and presented in height
mode by using nanoscope software (Digital Instruments Inc.).3. Results and discussion
We investigated the eﬀect of ectoine and hydroxyectoine on
Ab42 amyloid formation by using ThT-induced ﬂuorescence
and AFM. ThT-induced ﬂuorescence change was observed
for 72 h time period in the presence of Ab42 (25 lM), incu-
bated without/with ectoine or hydroxyectoine (25 lM, 1 mM,
10 mM and 100 mM) (Fig. 2). The Ab42 amyloid formation
followed a typical sigmoidal curve with an initial lag phase,
followed by phases of elongation and saturation. The lag time
for control samples was approximately 12 h, while the samples
coincubated with each of the solutes at 100 mM exhibited a lag
time of nearly 24 h. Compared to control Ab42 sample, the
samples co-incubated with ectoine or hydroxyectoine showed
less ﬂuorescence increase, indicating fewer cross b-sheets
formed in the samples. The inhibitory eﬀect of ectoine and
hydroxyectoine was found to be concentration-dependent,
while ectoine showed higher inhibitory eﬀect than hydroxyec-
toine. According to AFM images, the control sample con-
tained a high density of typical unbranched, Ab42 amyloid
ﬁbrils (Fig. 3A1 and A2). The ectoine 100 mM sample con-
tained few aggregates while no ﬁbrils could be observed
(Fig. 3B1 and B2). In the case of the hydroxyectoine
100 mM sample, more aggregates and a few ﬁbers could be ob-
served compared to ectoine samples (Fig. 3C1 and C2), whicht
Fig. 3. Representative AFM images of Ab42 samples incubated for 72 h without any ectoines (A1,A2), with 100 mM ectoine (B1,B2), and with
100 mM hydroxyectoine (C1,C2). Each sample picture represents a scan area of 5 · 5 lm taken twice at diﬀerent spots.
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hydroxyectoine itself aﬀected the binding of amyloid aggre-
gates to AFM mica surface (data not shown). The average
height of aggregates in the control, ectoine and hydroxyectoine
samples were found to be 6.98, 2.01, and 2.47 nm, respectively.
The eﬀect on cell viability was measured using seed sample
of Ab42 alone (25, 100 lM) and samples co-incubated with
ectoine and hydroxyectoine of concentrations 25 lM, 1 mM,
10 mM and 100 mM. As shown in Fig. 4A, the seed sample
containing Ab42 (25 lM) alone caused an approximate 25%
decrease in MTT activity compared to the control culture incu-
bated without Ab42, thereby indicating the toxicity of Ab42
aggregates. However, the samples co-incubated with both
Ab42 and ectoine showed a decrease in the MTT activity rang-
ing from 3% to 25%, depending on the concentration of
ectoine. Hydroxyectoine showed less eﬀect compared to
ectoine, causing MTT activity decrease, varying 18–27% from
that of the control culture. This result indicates that ectoinecould be a potential inhibitor for Ab42-induced toxicity while
hydroxyectoine could provide partial protection. The seed
samples with higher concentration of Ab42 (100 lM) showed
more toxicity compared to the 25 lM Ab42 samples
(Fig. 4B). The sample of 100 lM Ab42 alone showed a 43%
decrease in MTT activity while the samples coincubated with
ectoine showed 23–40% decrease in MTT activity. Seed sam-
ples prepared at pH 7.4 for 10 days were found to exhibit sim-
ilar eﬀects as Fig. 4 (data not shown). The eﬀect of ectoine or
hydroxyectoine alone on cell viability is shown in Fig. 5.
According to the result, ectoine/hydroxyectoine neither inhib-
its nor enhances the cell growth at up to 100 mM concentra-
tion. It is noteworthy that ectoines had been reported to be
biologically inert, i.e., they do not interfere with most enzy-
matic and binding reactions [32–36]. According to the reports,
ectoines are highly compatible with cell metabolism and toler-
ated in their producer organisms up to concentrations of 1 M.
Many microorganisms in nature, for example, Escherichia coli,
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Fig. 4. Dose response of SH-SY5Y apoptosis induced by: (A) Ab42 (25 lM) seed samples without/with ectoine or hydroxyectoine, (B) Ab42
(100 lM) seed samples without/with ectoine or hydroxyectoine. Seed samples were 100-times diluted in cell culture. Data are expressed as a fraction
of control value from two independent experiments with each experimental value being the average of four trials. The error bars were calculated with
a 95% conﬁdence level. Statistical analysis was performed by means of one-way analysis of variance (ANOVA). A P-value less than or equal to 0.05
was considered statistically signiﬁcant.
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from their environment to increase their stress resistance.
Considering that the physiological Ab concentrations in
human cerebral cortex are in the range of 3–8 nM [37], ectoines
may be needed in much lower concentrations for therapeutic
purpose than those used in this work. According to our results,
the inhibitory eﬀect of ectoines was dependent on the ratio be-
tween Ab and ectoines. As shown in Fig. 4, the eﬀect became
statistically signiﬁcant at above around 100-fold higher con-
centrations of ectoines than Ab, suggesting that the actual con-
centration of ectoines needed as drug candidates can be lower
than 1 lM. Since ectoines are zwitterionic low-molecularweight molecules at physiological conditions like many amino
acids, the penetration of ectoines through the blood brain bar-
rier in brain may not be highly aﬀected. Further experiments
on this issue need to be done in order to develop ectoines as
drug candidates for treating Alzheimers disease patients.
Lack of detailed structural information on soluble or aggre-
gated Ab had made structurebased drug design diﬃcult [10].
The residues 29–42 of Ab42 contain a large portion of nonpo-
lar amino acids. Recent reports suggest that p-stacking interac-
tions between aromatic residues of Ab may play a key role in
amyloid aggregation [10,38]. It is conceivable that ectoine and
hydroxyectoine may interfere with the hydrophobic and/or
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Fig. 5. Eﬀect of ectoine or hydroxyectoine alone on the viability of
SH-SY5Y in the absence of Ab42. Data are expressed as a fraction of
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mental value being the average of four trials. The error bars were
calculated with a 95% conﬁdence level.
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self-association of Ab42 into aggregates. The higher inhibitory
eﬀect of ectoine compared to hydroxyectoine might be due to
its higher hydrophobicity caused by the lack of hydroxyl group
in the ring structure.
According to our previous work [21], ectoine inhibited insu-
lin amyloid formation in vitro. Unlike Ab42 that is known to
be natively unfolded and random in conﬁguration [2,4,9,39],
insulin has a folded globular conformation under ambient
conditions [40–43]. Insulin had been reported to form amyloid
ﬁbrils via formation of partially unfolded intermediates from
the native globular form, triggered by various environmental
stresses. Considering those structural aspects, the inhibitory
action by ectoine on the insulin amyloid formation seems to
occur by stabilizing partially unfolded intermediates, not the
compact globular structure. Stabilization eﬀects of SMCs such
as ectoine and hydroxyectoine on proteins are not clearly
understood yet, but they are believed to be due to preferential
hydration and speciﬁc solute/protein interactions, resulting in
preferential exclusion of SMCs from protein monomers and
hydration of protein with solvent molecules [25,44,45]. Thus,
it is hypothesized here that the preferential hydration of (par-
tially) unfolded amyloidogenic proteins by ectoine and
hydroxyectoine may suppress the formation of amyloid ﬁbrils;
this possibility needs future investigation. The stabilization
might be further strengthened by speciﬁc hydrophobic interac-
tion between the solutes and protein, which can disrupt the
hydrogen bond formation between the partially unfolded
monomers.
In this work, ectoine and hydroxyectoine were found to
inhibit Ab42 amyloid formation and reduce the toxicity to
human neuroblastoma cells. Previously we demonstrated that
several SMCs successfully inhibited insulin amyloid formation
in vitro [21]. The inhibitory eﬀect of SMCs on amyloid forma-
tion is further strengthened by a recent report on the eﬃcacy
of trehalose against Huntington disease [46]. Supported by
those reports, current work suggests that naturally-occurring,non-toxic SMCs can be potential drug candidates against
the amyloid formation associated with neurodegenerative
disorders.
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